healio.com
Cure8 news brief
Why This Matters
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans and access issues.
Who Should Pay Attention
Adults and pediatric patients with Crohn’s, caregivers, clinicians prescribing IBD therapies, and patients already on biologics or oral therapies concerned about treatment choices and approvals.
Study Snapshot
Story typeResearch news
Evidence typePatient Education
Source depthFull source text
What To Know
The video is an expert perspective noting that multiple classes of medications are available for Crohn’s, including injectable biologics and an oral JAK inhibitor. It mentions recent approvals in the IL‑23 drug class and names several branded and generic agents.
It also points viewers to related videos on response predictors, head‑to‑head trials, cost/access issues, and pediatric considerations. If you want more detail: watch the full Healio video or read linked pieces for discussion of comparative effectiveness, predictors of response, costs, and pediatric management.
This transcript is an overview rather than an in‑depth review.
Keep In Mind
The content is a brief expert commentary (automatically transcribed) and does not report trial results or comparative data. It names therapies and classes but does not provide efficacy, safety, or prescribing details. For treatment decisions, consult a clinician and original study or guideline sources.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationhealio.com
Indexed viaBing News
Source typeResearch news
PublishedApr 23, 2025, 4:58 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Crohn's Disease Market Across The 7MM To Witness Upsurge In Growth From USD 9 Billion In 2023
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.
When are biologic drugs an option for Crohn’s disease?
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
Crohns' Disease Pipeline Appears Robust With 90+ Key Pharma Companies Actively ...
There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.